



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

Coats & Bennett/Medtronics  
1400 Crescent Green  
Suite 300  
Cary, NC 27518

APR 21 2008 In Re: Patent Term Extension  
Application for  
U.S. Patent No. 6,235,030

**NOTICE OF FINAL DETERMINATION**

A determination has been made that U.S. Patent No. 6,235,030, which claims the medical device X-STOP® Interspinous Process Decompression System, is eligible for patent term extension under 35 U.S.C. § 156. The period of extension has been determined to be 1,053 days.

A single request for reconsideration of this final determination as to the length of extension of the term of the patent may be made if filed within one month of the date of this notice. Extensions of time under 37 CFR § 1.136(a) are not applicable to this time period. In the absence of such request for reconsideration, the Director will issue a certificate of extension, under seal, for a period of 1,053 days.

The period of extension, if calculated using the Food and Drug Administration determination of the length of the regulatory review period published in the Federal Register of June 1, 2007 (72 Fed. Reg. 30596), would be 1,166 days. Under 35 U.S.C. § 156(c):

$$\begin{aligned}\text{Period of Extension} &= \frac{1}{2} (\text{Testing Phase}) + \text{Approval Phase} \\ &= \frac{1}{2} (1,538 - 578) + 686 \\ &= 1,166 \text{ days (3.2 years)}\end{aligned}$$

Since the regulatory review period began October 22, 1999, before the patent issued (May 22, 2001), only that portion of the regulatory review period occurring after the date the patent issued has been considered in the above determination of the length of the extension period 35 U.S.C. § 156(c). (From October 22, 1999, to and including May 22, 2001, is 578 days; this period is subtracted for the number of days occurring in the testing phase according to the FDA determination of the length of the regulatory review period.) No determination of a lack of due diligence under 35 U.S.C. § 156(c)(1) was made.

However, the 14 year exception of 35 U.S.C. § 156(c)(3) operates to limit the term of the extension in the present situation because it provides that the period remaining in the term of the patent measured from the date of approval of the approved product plus any patent term extension cannot exceed fourteen years. The period of extension calculated above, 1,166 days, would extend the patent from January 2, 2017 to May 21, 2018, which is beyond the 14-year limit (the approval date is November 21, 2005, thus the 14 year limit is November 21, 2019). The period of extension is thus limited to 1,053 days, by operation of 35 U.S.C. § 156(c)(3). Accordingly, the period of extension is the number of days to extend the term of the patent from its original expiration date, January 2, 2017, to and including November 21, 2019, or 1,053 days.

The limitations of 35 U.S.C. 156(g)(6) do not operate to further reduce the period of extension determined above.

Upon issuance of the certificate of extension, the following information will be published in the Official Gazette:

U.S. Patent No.:

6,235,030

Granted: May 22, 2001  
Original Expiration Date<sup>1</sup>: January 2, 2017  
Applicant: James F. Zucherman et al.  
Owner of Record: Kyphon Inc.  
Title: Spine Distraction Implant  
Product Trade Name: X-STOP® Interspinous Process Decompression System  
Term Extended: 1,053 days  
Expiration Date of Extension: November 21, 2019

---

<sup>1</sup>Subject to the provisions of 35 U.S.C. § 41(b).

Any correspondence with respect to this matter should be addressed as follows:

By mail: Mail Stop Hatch-Waxman PTE      By FAX: (571) 273-7755  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450.

Telephone inquiries related to this determination should be directed to the undersigned at (571) 272-7755.



Mary C. Tidwell  
Legal Advisor  
Office of Patent Legal Administration  
Office of the Deputy Commissioner  
for Patent Examination Policy

cc: Office of Regulatory Policy  
Food and Drug Administration  
10903 New Hampshire Ave., Bldg. 51, Rm. 6222  
Silver Spring, MD 20993-0002

Attention: Beverly Friedman

RE: X-STOP® Interspinous  
Process Decompression  
System  
FDA Docket No.: 2006E-0259